GLP‑1s and sex drive
Users and some clinicians are reporting that GLP‑1 drugs like Ozempic and Wegovy can affect libido and sexual health, an issue SELF explored as part of the larger social effects of these medications (self.com). That matters because sexual function is a core quality‑of‑life metric, so patients considering GLP‑1s should discuss potential changes with their clinicians up front (self.com).
These drugs were built to turn down hunger, but some people taking semaglutide medicines like Ozempic and Wegovy say the dial moved on sex too, with reports ranging from lower libido to less interest in dating and intimacy. SELF reported those accounts this week after interviewing users and clinicians who said the change can cut both ways. (self.com) Glucagon-like peptide-1 is a gut hormone your body releases after you eat, and the medicines copy that signal so the brain gets a stronger “you’ve had enough” message. Wegovy’s United States label describes semaglutide as a glucagon-like peptide-1 receptor agonist used for chronic weight management and cardiovascular risk reduction in some adults. (accessdata.fda.gov) That appetite signal does not stop at the stomach, because glucagon-like peptide-1 receptors also sit in brain circuits tied to reward and motivation. A 2026 narrative review said animal studies show activation of those pathways can suppress sexual motivation, while human evidence is still mixed and limited. (pubmed.ncbi.nlm.nih.gov) The human data are messy because the same drug can change several things at once, including body weight, blood sugar, nausea, fatigue, mood, and self-image. The same 2026 review found reports of decreased libido, erectile dysfunction, and orgasm problems in safety databases, but said those signals were not strong enough to prove a clear causal link. (pubmed.ncbi.nlm.nih.gov) There is also evidence pointing the other way. A 2022 meta-analysis of five randomized trials with 619 participants found weight loss improved erectile function in men with overweight or obesity, which means some people may feel better sexually as their metabolic health improves even if others feel worse. (onlinelibrary.wiley.com) One small controlled experiment in healthy lean men adds another wrinkle. A four-week crossover trial of dulaglutide, another glucagon-like peptide-1 drug, found no negative effect on sexual desire, reproductive hormones, or sperm measures, which suggests the medicines may not blunt sex drive directly in every body. (thelancet.com) But a 2025 database study in non-diabetic men with obesity found semaglutide use for weight loss was associated with higher rates of erectile dysfunction and testosterone deficiency diagnoses than matched controls. That kind of records study can show a pattern, not proof, because it cannot fully separate the drug itself from the people who were prescribed it. (nature.com) The official side-effect lists do not make libido the headline issue. Wegovy’s prescribing information highlights nausea, diarrhea, vomiting, constipation, abdominal pain, fatigue, dizziness, bloating, heartburn, and hair loss among the more common adverse reactions, so patients may not think to connect a sexual change to the medication unless a clinician asks. (wegovy.com) That leaves doctors and patients dealing with a quality-of-life question before the science is settled. The clearest takeaway from the current evidence and the reporting is that sexual changes on glucagon-like peptide-1 drugs appear real for some users, variable across users, and worth discussing before starting treatment rather than after a relationship suddenly feels different. (self.com)
